Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma
Introduction. Soft Tissue Sarcoma (STS) is a rare malignancy of mesodermal tissue, with international incidence estimates between 1.8 and 5 per 100,000 per year. Understanding quality of life (QoL) and the detrimental impact of disease progression is critical for long-term care and survival. Objecti...
Gespeichert in:
| Veröffentlicht in: | Complexity (New York, N.Y.) N.Y.), 2017, Vol.2017 (2017), p.1-8-006 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8-006 |
|---|---|
| container_issue | 2017 |
| container_start_page | 1 |
| container_title | Complexity (New York, N.Y.) |
| container_volume | 2017 |
| creator | Hudgens, Stacie Forsythe, Anna Kontoudis, Ilias D’Adamo, David Bird, Ashley Gelderblom, Hans |
| description | Introduction. Soft Tissue Sarcoma (STS) is a rare malignancy of mesodermal tissue, with international incidence estimates between 1.8 and 5 per 100,000 per year. Understanding quality of life (QoL) and the detrimental impact of disease progression is critical for long-term care and survival. Objectives. The primary objective was to explore the relationship between disease progression and health-related quality of life (HRQoL) using data from Eisai’s study (E7389-G000-309). Methods. This was a 1 : 1 randomized, open-label, multicenter, Phase 3 study comparing the efficacy and safety of eribulin versus dacarbazine in patients with advanced STS. The QoL analysis was conducted for the baseline and progression populations using the European Organization for Research and Treatment of Cancer 30-item core QoL questionnaire (EORTC QLQ-C30). Results. There were no statistical differences between the two treatment arms at baseline for any domain (p>0.05; n=452). Of the 399 patients who experienced disease progression (unadjusted and adjusting for histology), dacarbazine patients had significantly lower Global Health Status, Physical Functioning scores, and significantly worse Nausea and Vomiting, Insomnia, and Appetite Loss (p |
| doi_str_mv | 10.1155/2017/2372135 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5420413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A546648994</galeid><airiti_id>P20151222005_201712_201810220030_201810220030_1_8_006</airiti_id><sourcerecordid>A546648994</sourcerecordid><originalsourceid>FETCH-LOGICAL-a5145-957344b4ec9f115be24920569e9609bca976528cef4f6a7a52ab496e24c6f5993</originalsourceid><addsrcrecordid>eNqNkUtr3DAURk1padK0u66LoRACrRu9ZW0KIaQPGMiEpNCduHaksYLHSiU7If--Ep5mMll1pdfhXN37FcV7jL5gzPkxQVgeEyoJpvxFsY-RUhXiRLxMe8plJTH7vVe8ifEGIcQYZa-LPVJzTGit9ouLszvoJxidH0pvy4sJejc-5O3CWVPCWC6DXwUTYybcUC4Ta4Yxlvdu7MpLb8fyysU4mfISQuvX8LZ4ZaGP5t1mPSh-fTu7Ov1RLc6__zw9WVTAMeOV4pIy1jDTKpv6aAxhiiAulFECqaYFJQUndWssswIkcAINUyJhrbBcKXpQfJ29t1OzNtdt-lSAXt8Gt4bwoD04vfsyuE6v_J3mjCCGaRIcbQTB_5lMHPXaxdb0PQzGT1HjWimpCEG51sdn6I2fwpDay5RAok4pbKkV9Ea7wfpUt81SfcKZECwJWaIOn1CdgX7sou-nHEHcBT_PYBt8jMHYx94w0jl6naPXm-gT_uHpPB7hf1kn4NMMdG64hnv3nzqTGGNhS2MlJUEJWMwAuOBGt53IMnlSyTQ4NDsxyUuNUb6iaPeAda0REvQvoBLRdA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1896068201</pqid></control><display><type>article</type><title>Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma</title><source>Wiley Online Library Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Hudgens, Stacie ; Forsythe, Anna ; Kontoudis, Ilias ; D’Adamo, David ; Bird, Ashley ; Gelderblom, Hans</creator><contributor>Ferguson, Peter C.</contributor><creatorcontrib>Hudgens, Stacie ; Forsythe, Anna ; Kontoudis, Ilias ; D’Adamo, David ; Bird, Ashley ; Gelderblom, Hans ; Ferguson, Peter C.</creatorcontrib><description>Introduction. Soft Tissue Sarcoma (STS) is a rare malignancy of mesodermal tissue, with international incidence estimates between 1.8 and 5 per 100,000 per year. Understanding quality of life (QoL) and the detrimental impact of disease progression is critical for long-term care and survival. Objectives. The primary objective was to explore the relationship between disease progression and health-related quality of life (HRQoL) using data from Eisai’s study (E7389-G000-309). Methods. This was a 1 : 1 randomized, open-label, multicenter, Phase 3 study comparing the efficacy and safety of eribulin versus dacarbazine in patients with advanced STS. The QoL analysis was conducted for the baseline and progression populations using the European Organization for Research and Treatment of Cancer 30-item core QoL questionnaire (EORTC QLQ-C30). Results. There were no statistical differences between the two treatment arms at baseline for any domain (p>0.05; n=452). Of the 399 patients who experienced disease progression (unadjusted and adjusting for histology), dacarbazine patients had significantly lower Global Health Status, Physical Functioning scores, and significantly worse Nausea and Vomiting, Insomnia, and Appetite Loss (p<0.05). Conclusions. These results indicate differences in HRQoL overall and at progression between dacarbazine and eribulin patients, with increases in symptom severity observed among dacarbazine patients.</description><identifier>ISSN: 1357-714X</identifier><identifier>ISSN: 1076-2787</identifier><identifier>EISSN: 1099-0526</identifier><identifier>EISSN: 1369-1643</identifier><identifier>DOI: 10.1155/2017/2372135</identifier><identifier>PMID: 28512389</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Limiteds</publisher><subject>Analysis ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Clinical outcomes ; Clinical trials ; Development and progression ; Histology ; Long-term care of the sick ; Metastasis ; Oncology, Experimental ; Patients ; Quality of life ; Radiation therapy ; Sarcoma ; Studies ; Surgery</subject><ispartof>Complexity (New York, N.Y.), 2017, Vol.2017 (2017), p.1-8-006</ispartof><rights>Copyright © 2017 Stacie Hudgens et al.</rights><rights>COPYRIGHT 2017 John Wiley & Sons, Inc.</rights><rights>Copyright © 2017 Stacie Hudgens et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2017 Stacie Hudgens et al. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a5145-957344b4ec9f115be24920569e9609bca976528cef4f6a7a52ab496e24c6f5993</citedby><cites>FETCH-LOGICAL-a5145-957344b4ec9f115be24920569e9609bca976528cef4f6a7a52ab496e24c6f5993</cites><orcidid>0000-0002-7350-1549 ; 0000-0001-9270-8636</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420413/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5420413/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,4010,27900,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28512389$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Ferguson, Peter C.</contributor><creatorcontrib>Hudgens, Stacie</creatorcontrib><creatorcontrib>Forsythe, Anna</creatorcontrib><creatorcontrib>Kontoudis, Ilias</creatorcontrib><creatorcontrib>D’Adamo, David</creatorcontrib><creatorcontrib>Bird, Ashley</creatorcontrib><creatorcontrib>Gelderblom, Hans</creatorcontrib><title>Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma</title><title>Complexity (New York, N.Y.)</title><addtitle>Sarcoma</addtitle><description>Introduction. Soft Tissue Sarcoma (STS) is a rare malignancy of mesodermal tissue, with international incidence estimates between 1.8 and 5 per 100,000 per year. Understanding quality of life (QoL) and the detrimental impact of disease progression is critical for long-term care and survival. Objectives. The primary objective was to explore the relationship between disease progression and health-related quality of life (HRQoL) using data from Eisai’s study (E7389-G000-309). Methods. This was a 1 : 1 randomized, open-label, multicenter, Phase 3 study comparing the efficacy and safety of eribulin versus dacarbazine in patients with advanced STS. The QoL analysis was conducted for the baseline and progression populations using the European Organization for Research and Treatment of Cancer 30-item core QoL questionnaire (EORTC QLQ-C30). Results. There were no statistical differences between the two treatment arms at baseline for any domain (p>0.05; n=452). Of the 399 patients who experienced disease progression (unadjusted and adjusting for histology), dacarbazine patients had significantly lower Global Health Status, Physical Functioning scores, and significantly worse Nausea and Vomiting, Insomnia, and Appetite Loss (p<0.05). Conclusions. These results indicate differences in HRQoL overall and at progression between dacarbazine and eribulin patients, with increases in symptom severity observed among dacarbazine patients.</description><subject>Analysis</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>Development and progression</subject><subject>Histology</subject><subject>Long-term care of the sick</subject><subject>Metastasis</subject><subject>Oncology, Experimental</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Radiation therapy</subject><subject>Sarcoma</subject><subject>Studies</subject><subject>Surgery</subject><issn>1357-714X</issn><issn>1076-2787</issn><issn>1099-0526</issn><issn>1369-1643</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkUtr3DAURk1padK0u66LoRACrRu9ZW0KIaQPGMiEpNCduHaksYLHSiU7If--Ep5mMll1pdfhXN37FcV7jL5gzPkxQVgeEyoJpvxFsY-RUhXiRLxMe8plJTH7vVe8ifEGIcQYZa-LPVJzTGit9ouLszvoJxidH0pvy4sJejc-5O3CWVPCWC6DXwUTYybcUC4Ta4Yxlvdu7MpLb8fyysU4mfISQuvX8LZ4ZaGP5t1mPSh-fTu7Ov1RLc6__zw9WVTAMeOV4pIy1jDTKpv6aAxhiiAulFECqaYFJQUndWssswIkcAINUyJhrbBcKXpQfJ29t1OzNtdt-lSAXt8Gt4bwoD04vfsyuE6v_J3mjCCGaRIcbQTB_5lMHPXaxdb0PQzGT1HjWimpCEG51sdn6I2fwpDay5RAok4pbKkV9Ea7wfpUt81SfcKZECwJWaIOn1CdgX7sou-nHEHcBT_PYBt8jMHYx94w0jl6naPXm-gT_uHpPB7hf1kn4NMMdG64hnv3nzqTGGNhS2MlJUEJWMwAuOBGt53IMnlSyTQ4NDsxyUuNUb6iaPeAda0REvQvoBLRdA</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Hudgens, Stacie</creator><creator>Forsythe, Anna</creator><creator>Kontoudis, Ilias</creator><creator>D’Adamo, David</creator><creator>Bird, Ashley</creator><creator>Gelderblom, Hans</creator><general>Hindawi Limiteds</general><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>188</scope><scope>ADJCN</scope><scope>AHFXO</scope><scope>AHMDM</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>KB0</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7350-1549</orcidid><orcidid>https://orcid.org/0000-0001-9270-8636</orcidid></search><sort><creationdate>2017</creationdate><title>Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma</title><author>Hudgens, Stacie ; Forsythe, Anna ; Kontoudis, Ilias ; D’Adamo, David ; Bird, Ashley ; Gelderblom, Hans</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a5145-957344b4ec9f115be24920569e9609bca976528cef4f6a7a52ab496e24c6f5993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Analysis</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>Development and progression</topic><topic>Histology</topic><topic>Long-term care of the sick</topic><topic>Metastasis</topic><topic>Oncology, Experimental</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Radiation therapy</topic><topic>Sarcoma</topic><topic>Studies</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hudgens, Stacie</creatorcontrib><creatorcontrib>Forsythe, Anna</creatorcontrib><creatorcontrib>Kontoudis, Ilias</creatorcontrib><creatorcontrib>D’Adamo, David</creatorcontrib><creatorcontrib>Bird, Ashley</creatorcontrib><creatorcontrib>Gelderblom, Hans</creatorcontrib><collection>Airiti Library</collection><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>قاعدة العلوم الإنسانية - e-Marefa Humanities</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Research Library China</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Complexity (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hudgens, Stacie</au><au>Forsythe, Anna</au><au>Kontoudis, Ilias</au><au>D’Adamo, David</au><au>Bird, Ashley</au><au>Gelderblom, Hans</au><au>Ferguson, Peter C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma</atitle><jtitle>Complexity (New York, N.Y.)</jtitle><addtitle>Sarcoma</addtitle><date>2017</date><risdate>2017</risdate><volume>2017</volume><issue>2017</issue><spage>1</spage><epage>8-006</epage><pages>1-8-006</pages><issn>1357-714X</issn><issn>1076-2787</issn><eissn>1099-0526</eissn><eissn>1369-1643</eissn><abstract>Introduction. Soft Tissue Sarcoma (STS) is a rare malignancy of mesodermal tissue, with international incidence estimates between 1.8 and 5 per 100,000 per year. Understanding quality of life (QoL) and the detrimental impact of disease progression is critical for long-term care and survival. Objectives. The primary objective was to explore the relationship between disease progression and health-related quality of life (HRQoL) using data from Eisai’s study (E7389-G000-309). Methods. This was a 1 : 1 randomized, open-label, multicenter, Phase 3 study comparing the efficacy and safety of eribulin versus dacarbazine in patients with advanced STS. The QoL analysis was conducted for the baseline and progression populations using the European Organization for Research and Treatment of Cancer 30-item core QoL questionnaire (EORTC QLQ-C30). Results. There were no statistical differences between the two treatment arms at baseline for any domain (p>0.05; n=452). Of the 399 patients who experienced disease progression (unadjusted and adjusting for histology), dacarbazine patients had significantly lower Global Health Status, Physical Functioning scores, and significantly worse Nausea and Vomiting, Insomnia, and Appetite Loss (p<0.05). Conclusions. These results indicate differences in HRQoL overall and at progression between dacarbazine and eribulin patients, with increases in symptom severity observed among dacarbazine patients.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Limiteds</pub><pmid>28512389</pmid><doi>10.1155/2017/2372135</doi><orcidid>https://orcid.org/0000-0002-7350-1549</orcidid><orcidid>https://orcid.org/0000-0001-9270-8636</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1357-714X |
| ispartof | Complexity (New York, N.Y.), 2017, Vol.2017 (2017), p.1-8-006 |
| issn | 1357-714X 1076-2787 1099-0526 1369-1643 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5420413 |
| source | Wiley Online Library Open Access; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
| subjects | Analysis Cancer Cancer therapies Care and treatment Chemotherapy Clinical outcomes Clinical trials Development and progression Histology Long-term care of the sick Metastasis Oncology, Experimental Patients Quality of life Radiation therapy Sarcoma Studies Surgery |
| title | Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T23%3A01%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20Quality%20of%20Life%20at%20Progression%20in%20Patients%20with%20Soft%20Tissue%20Sarcoma&rft.jtitle=Complexity%20(New%20York,%20N.Y.)&rft.au=Hudgens,%20Stacie&rft.date=2017&rft.volume=2017&rft.issue=2017&rft.spage=1&rft.epage=8-006&rft.pages=1-8-006&rft.issn=1357-714X&rft.eissn=1099-0526&rft_id=info:doi/10.1155/2017/2372135&rft_dat=%3Cgale_pubme%3EA546648994%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1896068201&rft_id=info:pmid/28512389&rft_galeid=A546648994&rft_airiti_id=P20151222005_201712_201810220030_201810220030_1_8_006&rfr_iscdi=true |